Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection

Laurent Detalle, Thomas Stohr, Concepción Palomo, Pedro A. Piedra, Brian E. Gilbert, Vicente Mas, Andrena Millar, Ultan F. Power, Catelijne Stortelers, Koen Allosery, José A. Melero, Erik Depla
  • Antimicrobial Agents and Chemotherapy, October 2015, ASM Journals
  • DOI: 10.1128/aac.01802-15

What is it about?

Respiratory syncytial virus is the most common cause of severe lower respiratory tract disease in young infants. It is the main cause of bronchiolitis. However, there are no efficient drugs available to treat the infection. This paper describes a novel drug, ALX-0171, that neutralises respiratory syncytial virus much more potently than palivizumab, an antibody drug that is given prophylactically to infants at high risk of severe RSV disease. The pre-clinical data presented suggest that ALX-0171 looks very promising as a drug to treat RSV-infected infants.

Why is it important?

There are no drugs specifically against RSV currently available that effectively treat RSV infection. This paper presents data suggestion that ALX-0171 might have significant potential to treat RSV-mediated disease

Read Publication

The following have contributed to this page: Prof. Ultan F Power and Dr Laurent Detalle